Table 1.
Demographic and Clinical Characteristics of Patients, Siblings, and Control Subjects For Whom Both Genetic and Cognitive Data Were Available
| Patients | Siblings | Controls | Between-Group Comparisons | P | |
| n = 718 | n = 750 | n = 389 | Test Statistic | ||
| Age (SD) | 28.0 (8.2) | 27.4 (8.0) | 30.0 (10.4) | F = 12.22 | <.001 |
| Sex (% male) | 75.8 | 46.4 | 44.5 | χ2 = 162.7 | <.001 |
| IQ (SD) | 95.4 (16.5) | 102.6 (15.7) | 109.9 (14.8) | F = 112.8 | <.001 |
| Composite cognition score | −0.60 | −0.20 | 0.01 | F = 133.5 | <.001 |
| Age at onset of psychosis (SD) | 22.5 (6.8) | ||||
| Duration of illness in years (SD) | 4.4 (4.2) | ||||
| Recent onset psychosis (<1 y) | 17.1% | ||||
| Psychotic episodes (number) | 1.73 (1.12) | ||||
| PANSS score | |||||
| Positive | 1.81 (.77) | ||||
| Negative | 2.03 (.84) | ||||
| General | 1.76 (5.3) | ||||
| Current antipsychotics | 79.0% | ||||
| Mean dose a | 5.49 (20.44) | ||||
Note: PANSS, Positive and Negative Syndrome Scale.
a
Mean dose of antipsychotics in milligram per day haloperidol equivalents.